CN117050163B - Pichia pastoris engineering bacteria for secretory expression of recombinant type III collagen and application thereof - Google Patents
Pichia pastoris engineering bacteria for secretory expression of recombinant type III collagen and application thereof Download PDFInfo
- Publication number
- CN117050163B CN117050163B CN202311311778.XA CN202311311778A CN117050163B CN 117050163 B CN117050163 B CN 117050163B CN 202311311778 A CN202311311778 A CN 202311311778A CN 117050163 B CN117050163 B CN 117050163B
- Authority
- CN
- China
- Prior art keywords
- collagen
- recombinant
- type iii
- pichia pastoris
- iii collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000001187 Collagen Type III Human genes 0.000 title claims abstract description 42
- 108010069502 Collagen Type III Proteins 0.000 title claims abstract description 42
- 241000894006 Bacteria Species 0.000 title claims abstract description 25
- 241000235058 Komagataella pastoris Species 0.000 title claims abstract description 18
- 230000003248 secreting effect Effects 0.000 title abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 14
- 230000012292 cell migration Effects 0.000 claims abstract description 8
- 230000001737 promoting effect Effects 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 241001506991 Komagataella phaffii GS115 Species 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 230000002906 microbiologic effect Effects 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 abstract description 55
- 108010035532 Collagen Proteins 0.000 abstract description 55
- 229920001436 collagen Polymers 0.000 abstract description 55
- 108090000623 proteins and genes Proteins 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 6
- 150000001413 amino acids Chemical class 0.000 abstract description 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 3
- 230000028327 secretion Effects 0.000 abstract description 3
- 230000002900 effect on cell Effects 0.000 abstract description 2
- 239000012634 fragment Substances 0.000 description 34
- 239000013612 plasmid Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 230000029663 wound healing Effects 0.000 description 8
- 239000013642 negative control Substances 0.000 description 7
- 238000003259 recombinant expression Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 241000235648 Pichia Species 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 102000006495 integrins Human genes 0.000 description 5
- 108010044426 integrins Proteins 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 108091028732 Concatemer Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 241000403354 Microplus Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007469 bmm - medium Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/84—Pichia
Abstract
The application relates to the technical field of biology, and particularly discloses pichia pastoris engineering bacteria for secretory expression of recombinant type III collagen and application thereof. The amino acid sequence of the recombinant type III collagen is shown as (a) or (b): the amino acid sequence of (a) is shown as SEQ ID NO. 1; (b) The protein derived from the (a) which has collagen activity and is obtained by substituting, deleting or adding one or more amino acids in the amino acid sequence of the (a). The pichia pastoris engineering bacteria can be used for efficiently and safely carrying out extracellular secretion expression of the recombinant III type collagen, and the recombinant III type collagen has obvious promotion effect on cell proliferation and cell migration.
Description
Technical Field
The application relates to the field of biotechnology, in particular to pichia pastoris engineering bacteria for secretory expression of recombinant type III collagen and application thereof.
Background
In recent years, recombinant collagen benefits from the progress of synthetic biotechnology and the continuous expansion of application scenes, and has rapid growth. The recombinant collagen is prepared by adopting recombinant DNA technology in genetic engineering to carry out genetic manipulation and/or modification on genes encoding required human collagen, taking target genes into proper host cells (bacteria, yeast or other eukaryotic cells and the like) by using plasmids or viral vectors, expressing and translating the target genes into collagen or polypeptides similar to the collagen, extracting and purifying the target genes and the polypeptides. The genetic engineering method can avoid virus hidden danger, immune rejection reaction and the like; and the amino acid sequence consistency of the collagen formed naturally by the human body, the recombinant human-like collagen, the recombinant humanized collagen and the recombinant human collagen is gradually increased, so that the collagen is expected to be produced in a large scale at low cost and is the future direction of large-scale industrialized application of the collagen. Some businesses are currently producing collagen, recombinant short peptides or the like by recombinant expression techniques for commercial layout and commercialization.
The recombinant type III collagen is a full-length or partial amino acid sequence fragment containing the codes of collagen specific genes prepared by a DNA recombination technology, or a combination of collagen functional fragments, but the accurate screening of the amino acid sequence of a target functional region in a specific collagen complete gene is not easy, and the analysis of the full-chain length gene sequence of the protein is needed, so that the screening of the amino acid of a core functional region is ensured to have the expected efficacy.
Disclosure of Invention
The purpose of the application is to overcome the defects of the prior art and provide the pichia pastoris engineering bacteria for secretory expression of the recombinant III type collagen and the application thereof, and the pichia pastoris engineering bacteria can be used for efficiently and safely carrying out extracellular secretory expression of the recombinant III type collagen, and the recombinant III type collagen has obvious promotion effect on cell proliferation and cell migration.
In order to achieve the above purpose, the technical scheme adopted by the application is as follows:
in a first aspect, the present application provides a recombinant type III collagen having an amino acid sequence as set forth in (a) or (b):
(a) The amino acid sequence is shown as SEQ ID NO. 1;
(b) The protein derived from the (a) which has collagen activity and is obtained by substituting, deleting or adding one or more amino acids in the amino acid sequence of the (a).
The inventor of the application finds that a natural III type collagen integrin signal site or binding site sequence is adopted for splicing, then 12 repeated fragments are connected in series to form a recombinant expression collagen fragment (namely the recombinant III type collagen of the application), the total length of the recombinant expression collagen fragment is 525 amino acids, 1-171, 174-342 and 345-513 are identical human III type collagen fragments, RS connection is arranged between three human III type collagen fragments, and GPPGPCCGGG is adopted for modification after the human III type collagen fragments of 345-513 are subjected to the modification (the stability of the recombinant III type collagen can be improved), so that the recombinant III type collagen obtained by the application has obvious effects on cell proliferation and cell migration.
Due to the impact of the size of the collagen polypeptide on its secretion, too long a collagen polypeptide sequence (greater than 90 kDa) may not be secreted efficiently in pichia pastoris; too short a collagen polypeptide sequence would certainly increase the difficulty of the subsequent purification process. The application selects 12 repeated fragments in series to form a recombinant expression collagen fragment, so that the size of the fragment is controlled to be about 50 kDa.
In a second aspect, the present application provides a nucleic acid molecule encoding said recombinant type III collagen.
In a third aspect, the present application provides a vector carrying said nucleic acid molecule.
Redesign and optimize the nucleotide sequence of the recombinant III type collagen according to the selected amino acid sequence (shown as SEQ ID NO. 2), connect the nucleotide sequence of the recombinant III type collagen after optimization to a vector pGSI to obtain a plasmid pGSI-SEQ ID NO.2 containing the recombinant III type collagen (SEQ ID NO. 2), double-enzyme-cut pGSI-SEQ ID NO.2, and recycle the target fragment of the SEQ ID NO. 2; after single enzyme cutting pGSI-SEQ ID NO.2 to form linearization plasmid, the recovered T4 target fragment is connected in vitro to form two monomer concatemers pGSI- (SEQ ID NO. 2) 2 The method comprises the steps of carrying out a first treatment on the surface of the Single enzyme cutting pGSI- (SEQ ID NO. 2) 2 After formation of the linearized plasmid, the recovered fragment of SEQ ID NO.2 is ligated into the linearized plasmid pGSI- (SEQ ID NO. 2) 2 Becomes a triple tandem pGSI- (SEQ ID NO. 2) 3 The method comprises the steps of carrying out a first treatment on the surface of the pGSI- (SEQ ID NO. 2) with double enzyme cutting 3 Recovery (SEQ ID NO. 2) 3 A triset fragment of interest; after double cleavage of pPIC9K to form linearized plasmid, the plasmid is recovered (SEQ ID NO. 2) 3 The target fragment is connected with pPIC9K to form recombinant III collagen expression plasmid pPIC9K-rhCOL3S5.
Fourth, the present application provides genetically engineered bacteria expressing the recombinant type III collagen.
The method converts pichia pastoris GS115 through an electrotransformation method through linearization yeast expression plasmid pPIC9K-rhCOL3S5, directly selects single colony with better growth vigor on an MD culture medium plate to screen on a YPD culture medium plate containing high-concentration G418, and obtains the genetically engineered bacterium (high-copy recombinant yeast) of the method, so that the screening process of the high-copy recombinant yeast is simplified, the time cost of the stage is shortened, and the working efficiency is improved.
As a preferred embodiment of the genetically engineered bacterium, the genetically engineered bacterium is Pichia pastoris @Pichia pastoris) GS115/pPIC9K-rhCOL3S5-248b and Pichia pastorisPichia pastoris) GS115/pPIC9K-rhCOL3S5-523c, pichia pastorisPichia pastoris)GS115/pPIC9K-rhCOL3S5-248b has a preservation number of CGMCC No.27541, and the Pichia pastoris is preparedPichia pastoris) GS115/pPIC9K-rhCOL3S5-523c has a preservation number of CGMCC No.27542, and is preserved in China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) for 5 days of 6 months of 2023.
The genetically engineered bacterium can efficiently and safely carry out extracellular secretion expression of recombinant III type collagen.
As a preferred embodiment of the genetically engineered bacterium, the genetically engineered bacterium uses pPIC9K as an expression vector.
In a fifth aspect, the present application provides an agent for promoting cell proliferation, which comprises the recombinant type III collagen.
In a sixth aspect, the present application provides a cell migration promoting agent comprising the recombinant type III collagen.
The seventh object is to provide the application of the recombinant type III collagen in preparing a reagent for promoting cell proliferation or migration.
Eighth, the application provides an application of the genetically engineered bacterium in producing recombinant type III collagen, wherein the amino acid sequence of the recombinant type III collagen is shown as SEQ ID NO.1, and the nucleotide sequence of the recombinant type III collagen is shown as SEQ ID NO. 2.
The application uses BMM culture medium to induce and express fermentation supernatant of recombinant type III collagen, and the obtained recombinant type III collagen can be directly used for biological function detection through ammonium persulfate precipitation, dialysis and rapid purification of ultrafiltration. A process for precisely screening the functional fragments is established, and the process has short time and is beneficial to rapidly screening the functional fragments.
Compared with the prior art, the application has the following beneficial effects:
the recombinant type III collagen is obtained by splicing natural type III collagen integrin signal sites or binding site sequences, and then carrying out 12 repeated fragments in series to form a recombinant expression collagen fragment. The experimental result of CCK-8 method shows that the cell proliferation rate of ESF cells at the final concentration of 1.3 mg/mL and 0.5 mg/mL is 123.90% and 118.73%, which is obviously higher than that of the negative control group (1X maintenance medium), and the ESF cells are considered to have a certain effect of promoting the proliferation of the ESF cells. The cell scratch experiment result shows that the Wound healing percentage of 24 h of the negative control group (NC) is 59.71%, the Wound healing percentage of 24 h of the recombinant type III collagen sample group (WoundClosure%) of 0.2 mg/mL and 0.1 mg/mL is obviously larger than that of the negative control group (NC), and the Wound healing percentage is about 71.17% and 82.54% respectively, and the recombinant type III collagen sample groups of 0.2 mg/mL and 0.1 mg/mL are considered to have obvious effect of promoting HaCaT Wound healing.
Drawings
FIG. 1 is a plasmid map of recombinant type III collagen expression vector pPIC9K-rhCOL3S 5;
FIG. 2 is a plate diagram of the electric transformed Pichia pastoris GS 115;
FIG. 3 is a panel diagram of G418 screening;
FIG. 4 is a graph showing the results of PCR identification of positive clone strains;
FIG. 5 is a diagram showing the results of electrophoresis of the induced expression of 248b and 523c positive bacteria.
Detailed Description
For a better description of the objects, technical solutions and advantages of the present application, the present application will be further described with reference to the accompanying drawings and specific embodiments.
In the following examples, the experimental methods used are conventional methods unless otherwise specified, and the materials, reagents, etc. used are commercially available.
In the early experiment, the sequence of natural III type collagen integrin signal site or binding site is adopted to splice, and then 12 repeated segments are connected in series to form the design thought of recombinant expression collagen segment, so that more than 4 sequences are designed. Scoring is carried out according to a cytological efficacy detection result and the product purification difficulty (the separation and purification difficulty degree of a main band and a hydrolysis band is taken as judgment), and the scoring of the recombinant III type collagen is higher than that of other sequences.
EXAMPLE 1 construction of recombinant III collagen expression plasmid
In the embodiment, natural III type collagen integrin signal sites or binding site sequences are adopted for splicing, then 12 repeated fragments are connected in series to form a recombinant expression collagen fragment (namely recombinant III type collagen) with the total length of 525 amino acids, wherein 1-171, 174-342 and 345-513 are identical human III type collagen fragments, RS connection is arranged among three human III type collagen fragments, the human III type collagen fragment of 345-513 is modified by adopting GPPGPCCGGG, and the amino acid sequence of the recombinant III type collagen is shown as SEQ ID NO. 1.
According to the preference of pichia pastoris codons, the nucleotide sequence of the selected natural III type collagen integrin signal site or binding site is subjected to codon optimization by adopting the means, and the nucleotide sequence of the recombinant III type collagen is shown as SEQ ID NO. 2.
The nucleotide sequence (SEQ ID NO. 2) of recombinant type III collagen is synthesized by the Guangzhou Ai Ji biotechnology Co-Ltd and cloned to a vector pGSI to obtain a plasmid pGSI-SEQ ID NO.2 containing one recombinant type III collagen (SEQ ID NO. 2), and restriction enzyme sites of isotail enzymes BamHI and Bgl II are arranged at two ends of the SEQ ID NO.2 fragment.
(3) After BamH I and Bgl II double enzyme cutting pGSI-SEQ ID NO.2, recovering the fragment of SEQ ID NO. 2. After Bgl II single enzyme cuts pGSI-SEQ ID NO.2 to form linearization plasmid, the recovered T4 target fragment is connected in vitro to form tandem pGSI- (SEQ ID NO. 2) of two monomers 2 。
(4) Bgl II single enzyme cutting pGSI- (SEQ ID NO. 2) 2 After formation of the linearized plasmid, the recovered fragment of SEQ ID NO.2 is ligated into the linearized plasmid pGSI- (SEQ ID NO. 2) 2 Becomes a triple tandem pGSI- (SEQ ID NO. 2) 3 。
(5) EcoR I and Not I double enzyme cutting pGSI- (SEQ ID NO. 2) 3 After that, recovery (SEQ ID NO. 2) 3 The triset fragment of interest. EcoR I and Not I double enzyme cut pPIC9K to form linearization plasmid, will be recoveredIs (SEQ ID NO. 2) 3 The target fragment is connected with pPIC9K to form recombinant III collagen expression plasmid pPIC9K-rhCOL3S5. FIG. 1 is a plasmid map of recombinant type III collagen expression vector pPIC9K-rhCOL3S5.
EXAMPLE 2 construction of high-copy recombinant GS115/pPIC9K-rhCOL3S5 expressing recombinant type III collagen
The present example provides the construction of a high copy recombinant GS115/pPIC9K-rhCOL3S5 expressing recombinant type III collagen, comprising the steps of:
1) 20 mug of pPIC9K-rhCOL3S5 plasmid is extracted, and is subjected to tangential digestion by Sac I enzyme, and is purified and concentrated by an ethanol precipitation method for later use.
2) Electrotransformation pichia pastoris cell GS115: mu.L of electrotransformation competent GS115 and 10. Mu.g of recovered linearized plasmid were added to a sterile, ice-pre-chilled 1.5. 1.5 mL centrifuge tube and mixed well at the bottom of the flick tube to prepare an electrotransformation mixture. The above electrotransport mixture was transferred to a 0.2. 0.2 cm ice pre-chilled electrotransport cup, which was then ice-bathed for 5 min. The electric shock was performed using the sc2 electroporation program on a microplus electroporation machine. After the electric shock was completed, a sorbitol solution of 1M pre-cooled with 12 mL ice was immediately added, and the cells were mixed uniformly. The bacterial suspension was plated onto MD plates, one plate per 500. Mu.L of bacterial suspension, for a total of 10 plates. Plates were placed in an incubator at 29℃and incubated until single colonies appeared. Incubate at 29℃for about 4 days. FIG. 2 is a plate diagram of the electric transformed Pichia pastoris GS 115.
3) Screening of high copy recombinant yeasts: single colonies growing well on MD media plates were picked up and plated on YPD media plates containing 4.0. 4.0 mg/mL G418, and single colonies of Pichia pastoris GS115 (untransformed) were picked up and plated on YPD media plates containing 4.0. 4.0 mg/mL G418 using the same procedure as the control. The incubator was incubated at 29℃for about 5 days. FIG. 3 is a plate diagram of 4.0. 4.0 mg/mL G418 screen.
4) PCR identification of positive clone strains: after the plate developed colonies, single colonies 248b, 523c grown on the plate were picked with an inoculating loop and transferred to a 1.5 mL centrifuge tube containing 10. Mu.L of sterile water. After mixing, 1. Mu.L of 10U/. Mu.L of lysozyme was added and incubated at 30℃for 10 min. The sample was immersed in liquid nitrogen for 1 min and thawed at room temperature for about 5 min. Repeated 1 time. Briefly centrifuging, taking 1 μl of supernatant as a PCR reaction template, and using a vector-borne primer (5' - α -Factor: TACTATTGCCAGCATTGCTGC;
3' ″ AOX: GCAAATGGCATTCTGACATCC) PCR, the results are shown in FIG. 4.
Wherein M: DNA standard, 5000, 3000, 2000, 1500, 1000, 750, 500, 250, 100, bp from top to bottom; 1-2: PCR amplified fragments of colonies 248b, 523 c; 3: PCR amplified fragment of plasmid pPIC9K-rhCOL3S5 is used as positive control; 4: PCR amplified fragments of untransformed GS115 strain as negative control; 5: h 2 O as a blank.
Example 3 Induction expression, rapid purification and functional detection of recombinant type III collagen
Induction of expression: and selecting 248b and 523c positive bacteria for induction expression.
Positive strains 248b and 523c were inoculated into 250-mL Erlenmeyer flasks containing 25 mL of BMG medium, and incubated at 29℃and 250 rpm for about 24 h. Taking 2.5. 2.5 mL bacterial liquid from the cultured seed liquid, transferring to a 250 mL conical flask containing 22.5 mL BMG culture medium, culturing at 29 deg.C and 250 rpm at 18-22 h to OD 600 =6 or so. Subpackaging the bacterial liquid into a 50 mL centrifuge tube, centrifuging at 6000 rpm for 5 min at room temperature, discarding the supernatant, and collecting bacterial cells. The collected bacteria were resuspended to OD with the appropriate amount of BMM medium 600 After the resuspension, the bacterial suspension was transferred to 1L conical flasks for cultivation, each flask being 100 mL resuspended. The culture was performed at 29℃and 250 rpm for 72℃ 72 h. After the start of induction, methanol was added to a final concentration of 1% every 24. 24 h. After induction of expression 0, 24, 48, 72 and h, 10000 g was centrifuged for 10 min to collect fermentation supernatant, which was subjected to SDS-PAGE electrophoresis, and the electrophoresis results are shown in FIG. 5.
Wherein M: a protein standard; 1: positive strains induced to express the supernatant for 0 hours; 2: positive strains induced expression for 24 hours of supernatant; 3: positive strains induced expression of the supernatant for 48 hours; 4. positive strains induced expression of the supernatant for 72 hours; the 248b and 523c positive strains are respectively named as Pichia pastoris @, respectivelyPichia pastoris）GS115/pPIC9K-rhCOL3S5-248b and Pichia pastorisPichia pastoris) GS115/pPIC9K-rhCOL3S5-523c, the above strains were deposited in China general microbiological culture Collection center (accession number: beijing, chaoyang, north Chen Xi Lu 1, 3, china academy of sciences microbiological institute, postal code: 100101 Pichia pastorisPichia pastoris) GS115/pPIC9K-rhCOL3S5-248b and Pichia pastorisPichia pastoris) The preservation numbers of GS115/pPIC9K-rhCOL3S5-523c are CGMCC No.27541 and CGMCC No.27542 respectively.
And (3) quick purification: to the supernatant obtained above, 500 mL was added 121.5 g ammonium sulfate solids in portions in small amounts to a saturation concentration of 40% ammonium sulfate. And left standing at room temperature (25 ℃) for 1 h. Centrifuging at 25deg.C and 10000 g for 15 min, removing supernatant, and collecting precipitate. Finally, 5 mL of 1 XPBS (pH 7.2) was added, and the mixture was blown and mixed until the precipitate was completely dissolved. After adding the ammonium sulfate precipitation resuspension to a 10 kDa dialysis bag, the dialysis bag is placed in a 1L beaker containing 1000 mL purified water for dialysis, during which time the dialysate is changed 4-5 times for total dialysis of about 24 h. The collected dialysis retention liquid is subjected to ultrafiltration concentration by using a 10 kDa ultrafiltration tube, and the obtained ultrafiltration concentration liquid is used for subsequent biological function detection experiments.
And (3) function detection:
promotion of cell proliferation by recombinant type III collagen of the present application: the experimental result of the CCK-8 method shows that the cell proliferation rate of ESF cells at the final concentration of 1.3 mg/mL and 0.5 mg/mL is 123.90% and 118.73%, which is obviously higher than that of the negative control group (1X maintenance medium), and the ESF cells are considered to have a certain ESF cell proliferation promoting effect.
Promotion of cell migration by recombinant type III collagen of the present application: the cell scratch experiment result shows that the Wound healing percentage of 24 h of the negative control group (NC) is 59.71%, the Wound healing percentage of 24 h of the recombinant type III collagen sample group (WoundClosure%) of 0.2 mg/mL and 0.1 mg/mL is obviously larger than that of the negative control group (NC), and the Wound healing percentage is about 71.17% and 82.54% respectively, and the recombinant type III collagen sample groups of 0.2 mg/mL and 0.1 mg/mL are considered to have obvious effect of promoting HaCaT Wound healing.
Finally, it should be noted that the above embodiments are only for illustrating the technical solutions of the present application and not for limiting the scope of protection of the present application, and although the present application has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made to the technical solutions of the present application without departing from the spirit and scope of the technical solutions of the present application.
Claims (10)
1. The recombinant type III collagen is characterized in that the amino acid sequence of the recombinant type III collagen is shown as SEQ ID NO. 1.
2. A nucleic acid molecule encoding the recombinant type III collagen of claim 1.
3. A vector carrying the nucleic acid molecule of claim 2.
4. A genetically engineered bacterium expressing the recombinant type III collagen of claim 1.
5. The genetically engineered bacterium of claim 4, wherein the genetically engineered bacterium is Pichia pastoris (Pichia pastoris) GS115/pPIC9K-rhCOL3S5-248b and Pichia pastoris (Pichia pastoris) GS115/pPIC9K-rhCOL3S5-523c, wherein the Pichia pastoris GS115/pPIC9K-rhCOL3S5-248b has a accession number of CGMCC No.27541, and wherein the Pichia pastoris (Pichia pastoris) GS115/pPIC9K-rhCOL3S5-523c has a accession number of CGMCC No.27542, each of which has been deposited with the chinese microbiological bacterial culture collection center on day 6 and month 5 of 2023.
6. The genetically engineered bacterium of claim 5, wherein the genetically engineered bacterium comprises pPIC9K as an expression vector.
7. An agent for promoting cell proliferation, comprising the recombinant type III collagen according to claim 1.
8. A cell migration promoting agent comprising the recombinant type III collagen according to claim 1.
9. Use of recombinant type III collagen according to claim 1 for the preparation of a reagent for promoting cell proliferation or migration.
10. The application of the genetically engineered bacterium in the production of recombinant type III collagen, which is characterized in that the amino acid sequence of the recombinant type III collagen is shown as SEQ ID NO.1, and the nucleotide sequence of the recombinant type III collagen is shown as SEQ ID NO. 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311311778.XA CN117050163B (en) | 2023-10-11 | 2023-10-11 | Pichia pastoris engineering bacteria for secretory expression of recombinant type III collagen and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311311778.XA CN117050163B (en) | 2023-10-11 | 2023-10-11 | Pichia pastoris engineering bacteria for secretory expression of recombinant type III collagen and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117050163A CN117050163A (en) | 2023-11-14 |
| CN117050163B true CN117050163B (en) | 2024-01-19 |
Family
ID=88669571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311311778.XA Active CN117050163B (en) | 2023-10-11 | 2023-10-11 | Pichia pastoris engineering bacteria for secretory expression of recombinant type III collagen and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117050163B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103725623A (en) * | 2013-12-19 | 2014-04-16 | 西安巨子生物基因技术股份有限公司 | Pichia pastoris engineering bacteria of secretory expression human III type alpha chain collagen and construction method and application thereof |
| CN111363029A (en) * | 2018-12-25 | 2020-07-03 | 江苏江山聚源生物技术有限公司 | Recombinant human III-type collagen, expression strain and construction method thereof |
| CN115991764A (en) * | 2023-03-21 | 2023-04-21 | 杭州因智拓生物技术有限公司 | Hydroxyproline modified recombinant III type humanized collagen and preparation method and application thereof |
| CN116554305A (en) * | 2023-04-21 | 2023-08-08 | 广州易和生物科技有限公司 | Recombinant humanized III-type collagen, preparation method and application thereof |
| CN116813749A (en) * | 2023-06-13 | 2023-09-29 | 广州启点生物科技有限公司 | Recombinant humanized III type collagen and preparation method and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2485385A (en) * | 2010-11-12 | 2012-05-16 | Univ Manchester | Trimeric fusion protein comprising collagen and a prokaryotic/ viral trimerisation domain |
| JP2022532078A (en) * | 2019-05-08 | 2022-07-13 | アストラゼネカ アクチボラグ | Compositions for skin and wounds and methods of their use |
-
2023
- 2023-10-11 CN CN202311311778.XA patent/CN117050163B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103725623A (en) * | 2013-12-19 | 2014-04-16 | 西安巨子生物基因技术股份有限公司 | Pichia pastoris engineering bacteria of secretory expression human III type alpha chain collagen and construction method and application thereof |
| CN111363029A (en) * | 2018-12-25 | 2020-07-03 | 江苏江山聚源生物技术有限公司 | Recombinant human III-type collagen, expression strain and construction method thereof |
| CN115991764A (en) * | 2023-03-21 | 2023-04-21 | 杭州因智拓生物技术有限公司 | Hydroxyproline modified recombinant III type humanized collagen and preparation method and application thereof |
| CN116554305A (en) * | 2023-04-21 | 2023-08-08 | 广州易和生物科技有限公司 | Recombinant humanized III-type collagen, preparation method and application thereof |
| CN116813749A (en) * | 2023-06-13 | 2023-09-29 | 广州启点生物科技有限公司 | Recombinant humanized III type collagen and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117050163A (en) | 2023-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105061589B (en) | A kind of method of recombined human NTx albumen and its immobilization fermentation production | |
| CN109536525B (en) | A kind of Dunaliella salina chloroplast homologous recombination empty carrier and its application | |
| WO2024031921A1 (en) | Pichia pastoris with enhanced lactoferrin expression, method for constructing same, and use thereof | |
| CN112359035A (en) | Method for constructing protease K multi-copy strain | |
| CN113736817B (en) | Method for improving secretion efficiency and enzyme activity of alkaline lipase in pichia pastoris | |
| WO2023221787A1 (en) | Pichia pastoris engineering strain for recombinant type i collagen, construction method therefor and use thereof | |
| CN117050163B (en) | Pichia pastoris engineering bacteria for secretory expression of recombinant type III collagen and application thereof | |
| CN116555320A (en) | Recombinant human-derived III-type triple helix collagen engineering bacterium, and construction method and application thereof | |
| CN111363028B (en) | Recombinant human type I collagen, expression strain and construction method thereof | |
| CN116640205A (en) | Recombinant XVII type collagen and expression strain thereof | |
| CN115141763B (en) | Yeast engineering strain of efficient exocrine protein, construction method and application thereof | |
| CN116200279A (en) | Trichoderma reesei recombinant strain, preparation method and application thereof | |
| CN111500479B (en) | Construction and application of non-methanol-induced dual-promoter pichia pastoris engineering bacteria | |
| CN111925952B (en) | Pichia pastoris for efficiently expressing recombinant porcine alpha 1 interferon through auxiliary secretion | |
| CN104561063A (en) | cDNA fragment, high-efficiency expression recombinant plasmid and genetically engineered bacterium of bovine enterokinase and and expression method of genetically engineered bacterium | |
| CN108949579B (en) | Thermoascus thermophilus gene expression system | |
| CN115725634A (en) | Expression cassette of leghemoglobin, expression vector containing leghemoglobin, genetically engineered bacterium and application of leghemoglobin | |
| CN104046642B (en) | The method of the Dimerized fusion protein of fermenting and producing | |
| CN112522125A (en) | Hyaluronidase engineering bacterium and construction method and application thereof | |
| CN111893107A (en) | Pichia pastoris engineering strain for heterologous expression of cellulase gene EG IV and application | |
| CN113249234A (en) | Construction method of aspergillus niger genetically engineered bacterium for producing sodium gluconate and overexpressing CAT and GOD | |
| CN114250155A (en) | Trichoderma reesei engineering bacterium capable of highly producing cellulase under condition of taking glucose as carbon source and construction method and application thereof | |
| CN111926031A (en) | Method for improving secretion expression of porcine gamma interferon by pichia pastoris through multi-site integrated expression cassette | |
| CN111909916A (en) | Double-chain specific nuclease from euphausia superba and preparation method thereof | |
| CN109234276B (en) | Su-m1 promoter with improved transcription efficiency and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |